Interstitial lung disease following erlotinib (Tarceva®) in a patient who previously tolerated gefitinib (Iressa®)

Journal of Oncology Pharmacy Practice

Volumn 11, Issue 3, 2005, Pages 127-130

  Tammaro, Kelly A ^a   Baldwin, Patricia D ^a   Lundberg, Ante S ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Erlotinib; Gefitinib; Interstitial lung disease; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; OXYGEN; PACLITAXEL; PREDNISONE; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EARLY DIAGNOSIS; FREQUENCY ANALYSIS; HEMOPTYSIS; HUMAN; IMAGE ANALYSIS; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; OXYGEN THERAPY; PATIENT MONITORING; PELVIS CANCER; PRIORITY JOURNAL; SORE THROAT; SPINE METASTASIS; STEROID THERAPY; SYMPTOMATOLOGY; TREATMENT FAILURE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 27144495010     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155205jp158cr     Document Type: Article

References (8)

1. Lung Cancer. American Association of Cancer Research. Available at: http://www.aacr.org/page3018.aspx. Retrieved June 6, 2005.
2. Estimated New Cancer Cases and Deaths by Sex for All Sites, US, 2004. American Cancer Society, Inc., Surveillance Research 2004. Available at: http://www.cancer.org/docroot/MED/content/downloads/ MED_1_1x_CFF2004_page4.asp
3. The On-line Medical Dictionary CancerWEB 1997-2003. Available at: http://cancerweb.ncl.ac.uk/cgi-bin/omd?interstitial+lung+disease
4. Tarceva® (erlotinib) [product information]. Genentech, 2004.
5. Iressa® (gefitinib) [product information]. AstraZeneca, 2003.
6. Ramalingham S. Exploring the future of non-small cell lung cancer treatment. Supplement to Biotechnology Healthcare 2005; 1: 9-13.
7. Neelam ST, Kris MG, Pai W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005; 23: 165-74.
8. Kris MG, Natale RB, Herbst RS, et al. Efficacy of getitinib, an inhibitor of the epidermal growth factor receptor Tyrosine Kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003; 290: 2149-58.